Skip to main content

Advertisement

Fig. 4 | BMC Systems Biology

Fig. 4

From: Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity

Fig. 4

FLM gene activity scores differentiate the sensitive vs. resistant groups better than the relevant mutations (colored red) in each compound: a PLX4720, c Nutlin-3, e AZD6244, g Erlotinib. FLM scores improve prediction of drug sensitivity compared to gene expression, somatic mutation and copy number data separately: b PLX4720, p<0.00002, d Nutlin-3, p<0.06, f AZD6244, p<0.22, h Erlotinib using EGFR-KRAS predictor, p<0.01. We denote by * the significance level of 0.05

Back to article page